The TRAMPOLINE VT Study

  • Research type

    Research Study

  • Full title

    Critical Arrhythmogenic Sites In Human Ventricular Tachycardia: Mechanistic Insights And Determinants Of Clinical Outcomes From Non-Invasive Imaging And Ultra-High Density Activation Mapping

  • IRAS ID

    293735

  • Contact name

    Pier Lambiase

  • Contact email

    p.lambiase@nhs.net

  • Sponsor organisation

    Queen Mary University of London

  • Clinicaltrials.gov Identifier

    NCT05152784

  • Duration of Study in the UK

    2 years, 5 months, 30 days

  • Research summary

    People who have a weakened heart muscle – like those who have survived a heart attack or have a heart muscle disorder (cardiomyopathy) – are at risk of developing dangerous heart rhythms. These dangerous rhythms are known as ventricular tachycardia (VT) and ventricular fibrillation (VF), and they cause the heart to beat extremely fast. If VT or VF is not treated urgently (usually with an electrical shock known as ‘defibrillation’), this can be fatal. In the last few decades we have learnt to implant people at risk of these rhythms with internal cardioverter defibrillators (ICDs). These devices monitor the heart and deliver electrical shocks which can stop VT/VF, however the shocks are very unpleasant. \n\nTo try and prevent repeated episodes of VT/VF, we can perform an ablation procedure using wires inside the heart which burn away the source of these rhythms. Unfortunately, long term success rates for VT ablation are currently only moderate (about 50% effective). By combining data from MRI scans with new technology that creates more accurate electrical maps inside the heart, this project seeks to improve VT ablation accuracy and success rates, and will discover more about the mechanisms which cause this important arrhythmia.

  • REC name

    South West - Frenchay Research Ethics Committee

  • REC reference

    22/SW/0109

  • Date of REC Opinion

    8 Sep 2022

  • REC opinion

    Further Information Favourable Opinion